Assessment of Mexidol's effectiveness in the complex treatment of glaucomone neuropathy

Authors:
A.N. Bolatbekova, D.E. Kopbaeva, A.I. ARINOVA, B.S. Abrakhmanova

LLP "Center for Microsurgery of the Eye", Karaganda
KGP "Regional Clinical Hospital", Karaganda,
Karaganda State Medical University, Karaganda

Place of publication:
Labor hygiene and medical ecology. No. 2 (47), 2015

Summary:
the article analyzes the results of an open comparative study of the effectiveness and safety of the drug Mexidol in a dosage form for injection as part of therapy in patients with open -angle glaucoma of various stages. During the clinical study, the good tolerance of the drug Mexidol in the dosage form is confirmed by the injection solution when prescribing it to patients with various stages of open -angle glaucoma in doses of 100-300 mg/day. intramuscularly within 14–21 days. It was proposed to include Mexidol, a multifaceted effect, in the composition of the complex therapy of patients of various stages, which has a multifaceted effect. The identified unwanted phenomena related to the prescription of this therapy are not serious, and the probability of their appearance is taken into account in the instructions for the medical use of the studied drugs. Thanks to membrane, nootropic, anti -hypoxic and antioxidant effects, Mexidol is recommended to be used in the complex therapy of optical neuropathy in the early and later stages of the disease.